Global Ivosidenib Drugs Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Ivosidenib Drugs Market Insights, Forecast to 2034
Ivosidenib is an experimental drug for treatment of cancer. It is a small molecule inhibitor of IDH1, which is mutated in several forms of cancer.
Global Ivosidenib Drugs market is expected to reach to US$ 180 million in 2024, with a positive growth of %, compared with US$ 175.3 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Ivosidenib Drugs industry is evaluated to reach US$ 238.5 million in 2029. The CAGR will be 4.8% during 2024 to 2029.
Ivosidenib's market driver is its efficacy in treating relapsed or refractory acute myeloid leukemia (AML) with IDH1 mutations. It inhibits the mutated IDH1 enzyme, leading to remission. The niche target population and limited treatment options contribute to its growth. However, challenges include potential side effects, the need for genetic testing to identify eligible patients, and competition from other AML therapies. Despite challenges, Ivosidenib's promising results and ongoing research in AML with IDH1 mutations present opportunities for market expansion.
Report Covers
This report presents an overview of global Ivosidenib Drugs market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Ivosidenib Drugs market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Servier Pharmaceuticals
Segment by Type
60 Tablets
30 Tablets
Hospital
Pharmacy
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
UK
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Ivosidenib Drugs plant distribution, commercial date of Ivosidenib Drugs, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Ivosidenib Drugs introduction, etc. Ivosidenib Drugs Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Ivosidenib Drugs
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Ivosidenib Drugs market is expected to reach to US$ 180 million in 2024, with a positive growth of %, compared with US$ 175.3 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Ivosidenib Drugs industry is evaluated to reach US$ 238.5 million in 2029. The CAGR will be 4.8% during 2024 to 2029.
Ivosidenib's market driver is its efficacy in treating relapsed or refractory acute myeloid leukemia (AML) with IDH1 mutations. It inhibits the mutated IDH1 enzyme, leading to remission. The niche target population and limited treatment options contribute to its growth. However, challenges include potential side effects, the need for genetic testing to identify eligible patients, and competition from other AML therapies. Despite challenges, Ivosidenib's promising results and ongoing research in AML with IDH1 mutations present opportunities for market expansion.
Report Covers
This report presents an overview of global Ivosidenib Drugs market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Ivosidenib Drugs market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Servier Pharmaceuticals
Segment by Type
60 Tablets
30 Tablets
Segment by Application
Hospital
Pharmacy
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
UK
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Ivosidenib Drugs plant distribution, commercial date of Ivosidenib Drugs, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Ivosidenib Drugs introduction, etc. Ivosidenib Drugs Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Ivosidenib Drugs
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices